Search results for: 'therapy device'

08 Sep 2025  |  Global  |  Market Research

Growth Opportunities in Global Protein and Peptide Therapeutics, Forecast to 2030

Cross-Therapeutic Expansion is Driving Transformational Growth Fueled by Novel Formats and Smarter Delivery

Infographics

×

The protein and peptide therapeutics industry is undergoing a profound transformation, driven by next-generation biologics, including multi-specific antibodies, antibody-drug conjugates (ADCs), and GLP-1 treatments. These advances are intensifying competition, while the patent expiries of blockbuster antibodies are accelerating the entry of biosimi...

The pathology workforce shortage, accuracy concerns, and uneven distribution of prices and resources remain persistent challenges for the diagnostics sector. Automation, a broad concept encompassing processes and practices that streamline workflows, save time, and manage increasing workloads, has become a key response to these issues. By combining ...

Both predictive and prognostic biomarkers constitutes an central element in each and every targeted oncology drug discovery and development program. Breakthrough technologies allowing leveraging biomarkers for oncology are paving the way of personalized medicine and precision oncology. Indeed, oncology biomarkers provide the clinical community with...

The impressive advances in life sciences research and development (R&D) befallen in the past two-three years are playing a leading role in the transformation of the healthcare industry. A myriad of new developments in the fields of gene and cell therapies, empowered with nanotechnology advances, omics technologies and novel smart molecules approach...

As global clinical pipelines witness a surge in complex novel therapies, there is a general inclination toward improving trial design through adaptive trial designs with technology-enabled solutions for planning and execution. Artificial intelligence (AI) is gaining large-scale recognition in terms of supporting decentralized trial designs and allo...

This Frost & Sullivan research service discusses advances in AI integration in Molecular Diagnostics, highlights key advantages of incorporating AI in the diagnostics workflow and roadblocks that have prevented it from becoming mainstream. While AI is widely used in radiology- and pathology-based diagnostics, its adoption is gradually increasing in...

In 2003, the first human genome sequence was produced, with a production cost between $500 million and $1 billion. However, since 2008, when next-generation sequencing (NGS) approaches entered the research setting, there has been a significant decline in sequencing costs. These approaches allow either the whole genome (via whole-genome sequencing [...

The COVID-19 pandemic led to the rapid scaling up of production activities in the pharmaceutical industry. An increase in the number of FDA approvals in biologics has further accelerated biopharmaceutical production, particularly in North America and Asia. With a boom in biopharmaceuticals anticipated in the next 5 to 7 years, the demand for single...

The healthcare industry was hit hard by the pandemic as it tackled the toughest of challenges around the globe- slowing down the virus, managing hospital capacity, keeping its staff safe, and ensuring patient privacy and confidentiality. Contact centers were busy far beyond capacity, driving organizations of all sizes to accelerate investments in s...